NutraIngredients · April 21, 2026

Representative Maxine Dexter (D-OR) introduced the House version of the Dietary Supplement Listing Act of 2026, mirroring Senator Dick Durbin’s Senate companion bill from January. The legislation would require manufacturers to register product labels, ingredient lists, allergen statements, and structure-function claims in a publicly searchable FDA database. The Council for Responsible Nutrition endorsed the measure, while the Natural Products Association continues to oppose it as duplicative of existing DSHEA authority.

NutraIngredients · April 23, 2026

The Federal Trade Commission announced a $750,000 settlement with Vanilla Chip LLC, operator of TruHeight, for marketing protein shakes, gummies, and capsules as clinically proven to increase children’s height without competent scientific evidence. The order also bars the company from using employee-written or incentivized 5-star reviews on its website and third-party platforms. The case signals continued FTC focus on structure-function substantiation and testimonial integrity across the supplement category.

Federal Trade Commission · April 23, 2026

The FTC’s official release detailed a $4 million judgment, partially suspended for inability to pay, against Nevada-based Vanilla Chip LLC and its principals. Regulators specifically called out fabricated employee reviews and discount-for-review practices that misled parents shopping for child supplements. Industry counsel says the consent order sets a clearer compliance benchmark for any DSHEA marketer making developmental or pediatric structure-function claims.

Washington Monthly · April 22, 2026

Washington Monthly published a critical analysis of HHS Secretary Robert F. Kennedy Jr.’s push to deregulate unapproved peptides, arguing the policy returns these substances to a regulatory vacuum that overlaps with the dietary supplement framework. The piece notes that BPC-157, despite enthusiastic industry adoption, has only two clinical trials registered and limited published efficacy data. The article underscores ongoing tension between MAHA-aligned wellness priorities and DSHEA’s evidence-based ingredient framework.

Axios · April 23, 2026

Axios reported that the looming reclassification of more than a dozen peptide compounds out of FDA Category 2 could trigger a wellness category expansion rivaling the GLP-1 surge. Analysts expect compounding pharmacies and supplement makers to move quickly into peptide formulations once restrictions ease. The shift raises new questions about how peptides will interact with DSHEA’s drug exclusion clause if they enter the dietary supplement channel.

NutraIngredients · April 27, 2026

A Taiwan-based pilot trial found that 7 days of 1,200 mg daily NMN supplementation lowered TNF-alpha and other inflammatory cytokine expression in young men following blood flow restriction resistance exercise. The findings add to the growing human evidence base for NMN, the same ingredient FDA reinstated as a lawful dietary supplement in late 2025 after reversing its drug exclusion determination. NMN’s regulatory rebound continues to fuel commercial momentum across the longevity category.

Tufts Now · April 23, 2026

A new Tufts University analysis published in JAMA Network Open found that high-dose vitamin D supplementation reduced progression from prediabetes to type 2 diabetes by 19% in adults with AC or CC variants of the ApaI vitamin D receptor gene. The findings, drawn from a re-analysis of the D2d trial, reinforce the personalized-nutrition narrative the supplement industry has championed under DSHEA. Researchers cautioned consumers against self-prescribing high doses without genetic testing or clinical guidance.

NutraIngredients · April 27, 2026

Trend analytics platform Spate found searches for high blood pressure rose 423.5% year over year while custom probiotic queries surged more than 2,300%, indicating consumers now enter the supplement category symptom-first rather than brand-first. The data reflects how DSHEA’s structure-function claim framework is being tested by hyper-targeted, search-driven product positioning. Brands competing on specificity and personalization are best positioned to capture intent in 2026.

NutraIngredients · April 28, 2026

A Sermo survey of 374 US physicians found that 92% recommend dietary supplements and 94% have observed patient purchases tied directly to that guidance, casting physicians as the supplement industry’s primary credibility gatekeepers. Peer-reviewed clinical evidence drives 87% of physician confidence, with safety profile and ingredient transparency rounding out the top trust signals. The data reframes physician engagement as central to DSHEA-compliant marketing strategy.

Utah Public Radio · April 24, 2026

Utah Public Radio profiled the state’s $16 billion dietary supplement industry, the third-largest sector in Utah behind tech and tourism, while highlighting the limited state-level oversight applied to manufacturers. The piece notes that DSHEA’s federal framework remains the primary regulatory backbone even as states like New York pursue stricter mandates. Industry advocates argue federal preemption is essential to prevent a fragmented compliance landscape.

Your Voice Matters

The FDA’s public comment period on the scope of dietary supplement ingredients (Docket FDA-2026-N-2047) closed April 27, but engagement with Congress on the new House Dietary Supplement Listing Act has just begun. Tell your representatives where DSHEA’s future should land.